December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

30.27 -0.94 (-3.01%)
Streaming Delayed Price Updated: 3:17 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements. 
Via Benzinga
Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts
 
Via Benzinga
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
8 Analysts Assess Ultragenyx Pharmaceutical: What You Need To Know
 
Via Benzinga
Earnings Scheduled For August 5, 2025
 
Via Benzinga
What to Expect from Ultragenyx Pharmaceutical's Earnings
 
Via Benzinga
Ultragenyx (RARE) Q2 Revenue Up 13%
Via The Motley Fool
Topics Intellectual Property
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Reports Mixed Q2 2025 Earnings, Beats Revenue Estimates and Narrows Loss
Ultragenyx Q2 2025 earnings show revenue beat and narrower loss, reaffirming full-year guidance. Shares rose slightly post-report amid mixed market sentiment. 
Via Chartmill
Topics Earnings
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end. 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical Stock
 
Via Benzinga
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst
Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline. 
Via Benzinga
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection
The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer. 
Via Investor's Business Daily
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Market Monitor News July 11 BMO (Airline stocks UP - Ultragenyx Pharmaceuticals DOWN)
Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show. 
Via Chartmill
Topics World Trade
Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views
 
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings
 
Via Benzinga
Which stocks are experiencing notable movement on Thursday?
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
US Stocks Mixed; Initial Jobless Claims Fall
 
Via Benzinga
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease
The study will continue onto a third and final analysis toward the end of the year. 
Via Investor's Business Daily
Thursday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year. 
Via Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.